PMID- 16527420
OWN - NLM
STAT- MEDLINE
DCOM- 20060606
LR  - 20181201
IS  - 0305-7372 (Print)
IS  - 0305-7372 (Linking)
VI  - 32
IP  - 3
DP  - 2006 May
TI  - Microtubule stabilizing agents: their molecular signaling consequences and the 
      potential for enhancement by drug combination.
PG  - 166-79
AB  - Microtubule stabilization by chemotherapy is a powerful weapon in the war against 
      cancer. Disruption of the mitotic spindle activates a number of signaling 
      pathways, with consequences that may protect the cell or lead to its death via 
      apoptosis. Taxol, the first microtubule stabilizing drug to be identified, has 
      been utilized successfully in the treatment of solid tumors for two decades. 
      Several features, however, make this drug less than ideal, and the search for 
      next generation stabilizing drugs with increased efficacy has been intense and 
      fruitful. Microtubule stabilizing agents (MSAs), including the taxanes, the 
      epothilones, discodermolide, laulimalide, and eleutherobin, form an important and 
      expanding family of chemotherapeutic agents. A strong understanding of their 
      molecular signaling consequences is essential to their value, particularly in 
      regard to their potential for combinatorial chemotherapy - the use of multiple 
      agents to enhance the efficacy of cancer treatment. Here we present a critical 
      review of research on the signaling mechanisms induced by MSAs, their relevance 
      to apoptosis, and their potential for exploitation by combinatorial therapy.
FAU - Bergstralh, Daniel T
AU  - Bergstralh DT
AD  - Lineberger Comprehensive Cancer Center, Curriculum in Genetics and Molecular 
      Biology, Campus Box #7295, University of North Carolina at Chapel Hill, Chapel 
      Hill, NC 27599-7295, USA.
FAU - Ting, Jenny P-Y
AU  - Ting JP
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20060309
PL  - Netherlands
TA  - Cancer Treat Rev
JT  - Cancer treatment reviews
JID - 7502030
RN  - 0 (Alkanes)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (BIRC5 protein, human)
RN  - 0 (Carbamates)
RN  - 0 (Diterpenes)
RN  - 0 (Epothilones)
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (Interleukin-1)
RN  - 0 (Interleukin-8)
RN  - 0 (Lactones)
RN  - 0 (Macrolides)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0 (NF-kappa B)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Pyrones)
RN  - 0 (Survivin)
RN  - 0 (Taxoids)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 0 (eleutherobin)
RN  - 0 (laulimalide)
RN  - DHG59994DN (discodermolide)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.22 (Maturation-Promoting Factor)
RN  - EC 2.7.12.2 (MAP Kinase Kinase 1)
RN  - EC 2.7.12.2 (MAP2K1 protein, human)
SB  - IM
MH  - Alkanes/pharmacology
MH  - Animals
MH  - Antineoplastic Agents/adverse effects/*pharmacology
MH  - Antineoplastic Combined Chemotherapy Protocols/pharmacology
MH  - Carbamates/pharmacology
MH  - Cyclooxygenase 2/metabolism
MH  - Diterpenes/pharmacology
MH  - Epothilones/pharmacology
MH  - Humans
MH  - Inhibitor of Apoptosis Proteins/metabolism
MH  - Interleukin-1/metabolism
MH  - Interleukin-8/metabolism
MH  - Lactones/pharmacology
MH  - MAP Kinase Kinase 1/metabolism
MH  - MAP Kinase Signaling System/drug effects
MH  - Macrolides
MH  - Maturation-Promoting Factor/metabolism
MH  - Microtubule-Associated Proteins/metabolism
MH  - Microtubules/*drug effects
MH  - NF-kappa B/metabolism
MH  - Neoplasm Proteins/metabolism
MH  - Neoplasms/drug therapy/metabolism
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Pyrones/pharmacology
MH  - Signal Transduction/drug effects
MH  - Survivin
MH  - Taxoids/pharmacology
MH  - Tumor Suppressor Protein p53/metabolism
RF  - 193
EDAT- 2006/03/11 09:00
MHDA- 2006/06/07 09:00
CRDT- 2006/03/11 09:00
PHST- 2005/12/16 00:00 [received]
PHST- 2006/01/10 00:00 [revised]
PHST- 2006/01/10 00:00 [accepted]
PHST- 2006/03/11 09:00 [pubmed]
PHST- 2006/06/07 09:00 [medline]
PHST- 2006/03/11 09:00 [entrez]
AID - S0305-7372(06)00011-9 [pii]
AID - 10.1016/j.ctrv.2006.01.004 [doi]
PST - ppublish
SO  - Cancer Treat Rev. 2006 May;32(3):166-79. doi: 10.1016/j.ctrv.2006.01.004. Epub 
      2006 Mar 9.